Compare Charles River Laboratories Intl. Inc (CRL) vs iShares MBS ETF (MBB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs iShares MBS ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $227.54 (market cap $11.14B), while iShares MBS ETF trades at $93.83. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, iShares MBS ETF nearer its low. Which is the better fit depends on your goals.
| CRL | MBB | |
|---|---|---|
Market Cap | $11.14B | — |
Sector | Health | — |
52-Week High | $233.60 | $96.91 |
52-Week Low | $145.57 | $92.46 |
Enterprise Value | $14.00B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
MBB, the iShares MBS ETF, trades at $93.26, down 0.49% on the day. The technical outlook is bearish, with moving averages signaling a downtrend, though oversold oscillators suggest potential for a near-term bounce. Recent news highlights institutional activity, with some firms increasing stakes while others reduced positions. The ETF continues its dividend distributions, with the latest payment scheduled for July 2026.
The outlook for MBB is mixed, balancing a defensive income stream from mortgage-backed securities against interest rate sensitivity. The primary opportunity lies in its monthly dividend yield, appealing for income-focused investors. Key risks include Federal Reserve policy shifts impacting bond valuations and broader economic conditions affecting the housing market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →
